Cancer clinical trials | Salem Health Cancer Institute | Salem, OR
If you are experiencing flu-like or COVID-19 symptoms, call us at 503-814-0099 before visiting any of our locations. Learn more.

Cancer clinical trials

Comparing accepted cancer treatments with new types of treatments


We are proud to offer patients innovative treatment options through clinical research trials. Our affiliation with the Knight Cancer Institute means that that we work closely with researchers to provide quality cancer care.

Our clinical trials are tailored to the needs of the community. We conduct phase II-IV drug trials as well as trials that include surgery and radiation therapy. We also offer quality-of-life trials.

We use the same ethical and professional guidelines as larger academic medical centers and often exceed those standards. We are subject to the same federal standards and oversight as nationally recognized institutions.

Nurse touching a senior man's shoulder

 

Talk with your doctor to see if clinical trials are an option for you. Or call our clinical research department at 503-814-1435.

 

Frequently asked questions about clinical trials

What is a clinical trial?
Why should I participate?
What are the risks of participation?
How do I know whether I can participate?
Will the treatment be free?
Are all the studies treatment studies?
Are all patients on chemotherapy studies treated in the hospital?
Can I drop out of the clinical trial?
What cancer clinical trials will Medicare pay for?
Are clinical trials monitored?

Expand all

Collapse all

 

 

Currently open cancer clinical trials

Connect® Myeloid Disease Registry

Tumor site: Hematologic (MDS, MF)

Description: Observational disease registry to provide insights into disease treatment decisions and patterns as they relate to patient-reported outcomes in patients with Myelodysplastic Syndromes (MDS) or Myelofibrosis (MF).

More info: view more about this trial at clinicaltrials.gov

     


    PATHFINDER 2

    Early Detection (no tumor site)

    Description: Interventional, prospective, multi-center study to evaluate the safety and performance of the GRAIL Multi-Cancer Early Detection (MCED) test in patients ages 50+ that have not been diagnosed with or treated for an invasive or hematologic malignancy within 3 years prior to enrollment.

    More info: view more about this trial at clinicaltrials.gov



      Augmented Reality-Based Education

      Tumor site: All sites

      Description: Interventional augmented reality based education study where participants view a personalized 3D rendition of their own radiotherapy treatment with the use of augmented reality technology via a portable tablet.

         


        S1703

        Tumor site: Breast

        Description: Interventional randomized non-inferiority trial comparing overall survival of patients with hormone receptor positive, Her2 negative metastatic breast cancer monitored with serum tumor marker directed disease monitoring versus the usual care.

        More info: view more about this trial at clinicaltrials.gov

           


          S1823

          Tumor site: Testicular, Ovarian 

          Description: Observational study to assess if the expression of plasma miRNA 371 is a predictor for outcome in patients with newly diagnosed germ cell tumors.

          More info: view more about this trial at clinicaltrials.gov